Evidence map›Paper›PMID 38500747›Full record

ArticleAmerican journal of nuclear medicine and molecular imaging2024

Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.

Lizhi Zhu, Peng Chen, Zhongqiu Guo, Fangdu Li, Xiu Luo, Xia Du, Liying Zhang, Changjing Zuo, Xiao Li

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lizhi ZhuDepartment of Nuclear Medicine, Shanghai Changhai Hospital Shanghai 200433, China.
Peng ChenDepartment of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Zhongqiu GuoDepartment of Nuclear Medicine, Shanghai Changhai Hospital Shanghai 200433, China.
Fangdu LiDepartment of Nuclear Medicine, Liqun Hospital Putuo District, Shanghai 200333, China.
Xiu LuoDepartment of Nuclear Medicine, Shanghai Changhai Hospital Shanghai 200433, China.
Xia DuDepartment of Radiology, The Affiliated Hospital of Guizhou Medical University Guiyang 550004, Guizhou, China.
Liying ZhangDepartment of Nuclear Medicine, Liqun Hospital Putuo District, Shanghai 200333, China.
Changjing ZuoDepartment of Nuclear Medicine, Shanghai Changhai Hospital Shanghai 200433, China.
Xiao LiDepartment of Nuclear Medicine, Shanghai Changhai Hospital Shanghai 200433, China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors are often with complex and heterogeneous biological processes, such as glycometabolism and fibrosis, which are the main biochemical pathways that determine therapeutic effects. Specifically, this study aims to assess the diagnosing performance of

Indexed as

bone metastasesfibroblast activation proteinfibrosisglycometabolismheterogeneityMolecular imagingprostate cancerprostate-specific membrane antigen

Identifiers

PMID38500747
PMCPMC10944373
OpenAlexW4394758520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.